VANCOUVER, Aug. 29 /CNW/ - Chemokine Therapeutics Corp. (the “Company”) (TSX:CTI; OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent 7,091,310 B2 relating to chemokine analogs for the treatment of human disease.
